Targets › COMT
1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Dec 2029.
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol. (UniProt, P21964)
Open in Phaseline: the race on COMT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Satish R. Raj | Entacapone Catechol O-methyltransferase inhibitor | COMT | Phase 1 | Tachycardia | Dec 2029 |
Tachycardia (1)
mixed (1)
Satish R. Raj (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.